

Supplementary information

Cyclodextrin-based hybrid polymeric complex to overcome dual drug resistance mechanisms for cancer therapy

Lingjie Ke^{1,†}, Zhiguo Li^{1,†}, Xiaoshan Fan², Xian Jun Loh³, Hongwei Cheng^{1,*}, Yun-long Wu^{1,*} and Zibiao Li^{3,*}

¹School of pharmaceutical science, Xiamen University, Xiamen 361102, China;
32320191153429@stu.xmu.edu.cn (L.J.K.), lizhiguo@stu.xmu.edu.cn (Z.G.L),
hongwei1026c@163.com (H.W.C)

²State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Donghua University, Shanghai 201620, China; xsfan@dhu.edu.cn.

³Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A*STAR), 2 Fusionopolis Way, #08-03 Innovis, Singapore 138634, Singapore

*Correspondence: hongwei1026c@163.com (H.W.C); lizb@imre.a-star.edu.sg (Z.L.); Tel.: +65-6319-4767 (Z.L.)

Supporting Figures




Figure S1. ^1H NMR spectra of $\beta\text{-CD-PCL-PDMAEMA}$, CDCl_3 as solvent.




Figure S2. Enrichment analysis of doxorubicin-resistant hepatoma cells in GSE125180.




Figure S3. MDR1 and Bcl-2 are overexpressed in several cancer types.




Figure S4. The Luciferase expression efficiency of PEI-25k only, β -CD-PCL-PDMAEMA/Nur77 Δ DBD, inclusion complex/Nur77 Δ DBD complexes (gradient weight ratios, from 0 to 10) incubated with HepG2 cells.




Figure S5. Combination index (CI) of DOX and Nur77 Δ DBD in inclusion complex/Nur77 Δ DBD-DOX against HepG2/MDR1-Bcl2 cells as a function of fraction affected (f_a) determined via Chou-Talalay's isobolographic method and software CompuSyn.